Evidence map›Paper›PMID 36509464›Full record

ArticleJournal of gynecologic oncology2023

Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.

Jin Hwa Hong, Hyun Woong Cho, Yung-Taek Ouh, Jae Kwan Lee, Yikyeong Chun

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gynecologic oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jin Hwa HongDepartment of Obstetrics and Gynecology, Guro Hospital, Korea University College of Medicine, Seoul, Korea.ORCID 0000-0002-6905-5363
Hyun Woong ChoDepartment of Obstetrics and Gynecology, Guro Hospital, Korea University College of Medicine, Seoul, Korea.ORCID 0000-0002-0724-9971
Yung-Taek OuhDepartment of Obstetrics and Gynecology, School of Medicine, Kangwon National University, Chuncheon, Korea.ORCID 0000-0001-5887-4497
Jae Kwan LeeDepartment of Obstetrics and Gynecology, Guro Hospital, Korea University College of Medicine, Seoul, Korea.ORCID 0000-0003-3101-6403
Yikyeong ChunDepartment of Pathology, Guro Hospital, Korea University College of Medicine, Seoul, Korea. ykcmd@naver.com.ORCID 0000-0002-4235-9690
Korea University Medical Center · KRKangwon National University · KR

Funding

Korea University Guro Hospital K2117211
6 · The paper itself

Abstract

objectiveImmune checkpoint inhibitors have been widely used in the treatment of endometrial cancer (EC) with microsatellite instability-hypermutated (MSI-H). However, there is an unmet need for microsatellite stable (MSS) EC because of their modest activity. This study aimed to identify potential immune-related biomarkers in MSS EC.

methodsOne hundred and twenty-three patients with EC who underwent hysterectomy were enrolled. MSI status was determined using MSI analysis and/or immunohistochemical staining for mismatch repair proteins. Immunohistochemical analysis of programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), PD-L2, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), cluster of differentiation 3 (CD3), CD8, lymphocyte activation gene-3 (LAG-3), indoleamine 2,3-dioxygenase 1 (IDO1), phosphatase and tensin homolog (PTEN), p53, AT-rich interactive domain-containing protein 1A (ARID1A), and β-catenin was performed using tissue microarray blocks.

resultsAmong 123 patients, 95 (77.2%) were classified as having MSS. Within EC with MSS, PD-L1 positivity was significantly associated with positive PD-1 (p<0.001), CTLA-4 (p<0.001), CD3 (p=0.002), CD8 (p<0.001), and LAG-3 (p<0.001). In the univariate analysis, positive PD-1 (odds ratio [OR]=9.281; 95% confidence interval [CI]=2.560-33.653; p<0.001), CTLA-4 (OR=5.33; 95% CI=1.418-19.307; p=0.005), CD3 (OR=5.571; 95% CI=1.746-17.775; p=0.004), CD8 (OR=6.909; 95% CI=2.647-18.037; p<0.001), and LAG-3 (OR=9.75; 95% CI=1.947-48.828; p=0.005) were significantly associated with PD-L1 positivity in MSS EC. In the multivariate analysis, LAG-3 demonstrated a significant association with positive PD-L1 expression in MSS EC (OR=5.061; 95% CI=1.534-16.693; p=0.023).

conclusionIn patients with MSS EC harboring PD-L1, LAG-3 may be a potential immunotherapeutic target. Clinical trials investigating the role of anti-LAG-3 antibodies, alone or in combination with other immunotherapies, are warranted.

Indexed as

Carcinoma, EndometrioidEndometrial NeoplasmsB7-H1 AntigenCTLA-4 AntigenFemaleHumansImmunotherapyLymphocyte ActivationLymphocyte Activation Gene 3 ProteinMicrosatellite RepeatsProgrammed Cell Death 1 ReceptorB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenLymphocyte Activation Gene 3 ProteinProgrammed Cell Death 1 ReceptorEndometrial NeoplasmsLymphocyte Activation Gene-3Microsatellite StableProgrammed Cell Death-Ligand 1

Identifiers

PMID36509464
PMCPMC9995863
OpenAlexW4311118877

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.